Malaria Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others), By Drug Formulation (Tablets, Capsules, Injectables, Others), By End User (Adults, Children, Pregnant Women, Others), By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies) By Region, and Competition Forecast

Global Malaria Therapeutics market is anticipated to grow considerably in the forecast period of 2028 due to the ongoing Investments in malaria research and development for eradicating malaria globally. According to the World Health Organization (WHO), in 2020, there were an estimated 229 million cases of malaria globally, with an estimated 409,000 deaths.

Malaria is a potentially life-threatening disease caused by parasites transmitted to humans through the bites of infected female mosquitoes. The parasites responsible for malaria are of the Plasmodium species, with Plasmodium falciparum being the most deadly. Malaria is prevalent in tropical and subtropical regions, particularly in sub-Saharan Africa, where it is a leading cause of morbidity and mortality. Treatment for malaria involves the use of antimalarial medications, which can vary depending on the type and severity of the infection. It is important to seek prompt medical attention if you suspect you have contracted malaria. Malaria is a serious disease and can be fatal if not treated promptly and appropriately.

Malaria therapeutics have a significant impact on patients who are infected with malaria. Malaria therapeutics help to alleviate the symptoms of the disease and prevent it from progressing to severe disease. Effective treatment can reduce the duration and severity of the illness, and prevent complications and long-term health problems. In addition to their direct impact on patients, malaria therapeutics also have broader impacts on public health and society, thereby supporting the growth of global malaria therapeutics market. Effective treatment can reduce the spread of the disease and prevent the development of drug-resistant strains of the parasite. This, in turn, can help to reduce the burden of the disease on healthcare systems and economies.

However, access to malaria therapeutics remains a significant challenge in many regions of the world where malaria is endemic, thereby hampering the growth of global malaria therapeutics market. Limited healthcare infrastructure, high treatment costs, and other barriers to access can prevent patients from receiving the care they need. Efforts to improve access to malaria therapeutics, such as through the development of affordable and accessible drugs and diagnostic tests, are crucial for improving patient outcomes and reducing the global burden of malaria. In 2020, 46 countries reported an increase in malaria cases, with 26 of these countries reporting more than a 20% increase. Children under the age of five are the most vulnerable group affected by malaria, accounting for an estimated 67% of all malaria deaths worldwide in 2020.

Growing incidence of malaria is boosting the Malaria Therapeutics Market

Increased demand for malaria therapeutics as the number of malaria cases increases, there is a greater demand for effective treatments. This presents a significant market opportunity for pharmaceutical companies developing malaria therapeutics.Malaria is a costly disease to treat, both in terms of direct medical expenses and lost productivity. As the incidence of malaria increases, healthcare systems may struggle to keep up with the demand for treatment and prevention, which could lead to increased costs. Malaria can cause severe illness and death, particularly among young children and pregnant women. The growing incidence of malaria means that more people are at risk of contracting the disease, which could lead to increased morbidity and mortality.

Malaria is a significant barrier to economic development in many countries, particularly those in sub-Saharan Africa. The disease can lead to lost productivity, increased healthcare costs, and decreased investment. As the incidence of malaria increases, these impacts may become more pronounced.

Malaria is a significant public health problem in many tropical and subtropical regions of the world, particularly in sub-Saharan Africa, where more than 90% of malaria cases and deaths occur. However, malaria also affects other parts of the world, including Asia, Latin America, and the Middle East. The incidence of malaria has been increasing in several countries in recent years, partly due to factors such as climate change, insecticide resistance, and the lack of access to effective prevention and treatment. In addition, political instability, Efforts to control and eliminate malaria include the use of insecticide-treated bed nets, indoor residual spraying, and antimalarial drugs. However, these efforts face several challenges, including limited funding, inadequate healthcare infrastructure, and the emergence of drug-resistant strains of the parasite.

Therefore, the growing incidence of malaria in several countries is a significant public health challenge that requires a comprehensive and sustained effort to address, thereby supporting the growth of global malaria therapeutics market.

Increasing investment in malaria research is Driving the Demand for Malaria Therapeutics in the Market

Increasing investment in malaria research is driving the demand for malaria therapeutics in the market. Investment in malaria research can lead to the development of new and improved malaria therapeutics, such as drugs and vaccines. These therapeutics can then be marketed and sold to individuals and organizations that are involved in the prevention and treatment of malaria.

In addition to driving demand for malaria therapeutics, increased investment in malaria research can also lead to the creation of new businesses and job opportunities in the pharmaceutical industry. This can have a positive impact on the economy and provide benefits for individuals and communities. Additionally, investment in malaria research is essential to address the global burden of malaria and improve the health outcomes of individuals who are affected by the disease. By driving demand for malaria therapeutics, such investment can play a critical role in achieving these goals.

Investment in malaria research can also lead to increased access to malaria interventions, such as mosquito nets, diagnostic tests, and antimalarial drugs. This can help prevent the spread of the disease and reduce the number of cases and deaths. Investment in malaria research can help strengthen health systems in malaria-endemic countries, leading to improved health outcomes for the population. This can include training healthcare workers, improving healthcare infrastructure, and increasing access to healthcare services.

Malaria disproportionately affects the most vulnerable populations, such as children under five and pregnant women. Increasing investment in malaria research can help reduce health inequities by improving access to prevention and treatment options for these populations.

Investment in malaria research can lead to the development of effective interventions such as vaccines, drugs, and insecticides. These interventions can then be used across multiple countries, leading to a reduction in the burden of malaria in those regions.

Furthermore, Investment in malaria research also lead to increased collaboration between researchers, healthcare providers, and governments across multiple countries. This collaboration can help share best practices and information, leading to better prevention and treatment of malaria across borders.

Additionally, Investment in malaria research can also have an impact on global health security. Malaria is a global health threat, and investing in research can help prevent the spread of the disease across borders and reduce the risk of epidemics.Malaria can cause significant morbidity, leading to long-term health problems in those who survive the disease. Investing in malaria research can help improve health outcomes by reducing the number of cases and the severity of the disease.

Favorable Government initiatives and Policies Drives the Malaria Therapeutics Market Growth

Favorable government initiatives and policies can play a significant role in driving the growth of the malaria therapeutics market. Malaria is a life-threatening disease that affects millions of people globally, particularly in developing countries. To combat the disease, governments across the world have launched various initiatives to promote the development and distribution of malaria therapeutics.

For instance, many governments have allocated significant funds for research and development activities focused on developing effective malaria therapeutics. In addition, governments have also launched programs to increase the accessibility of malaria medications to patients. This includes initiatives aimed at improving the supply chain, reducing the cost of medicines, and increasing awareness among patients.

Furthermore, various policies, such as tax incentives and regulatory frameworks, have been put in place to encourage investment in the global malaria therapeutics market. These policies can help to attract pharmaceutical companies and other stakeholders to invest in research and development activities, leading to the development of new and more effective malaria therapeutics. One of the most significant government initiatives is the Global Fund to Fight AIDS, Tuberculosis and Malaria. The Global Fund is a partnership between governments, civil society, the private sector, and affected communities, and it provides funding for programs aimed at reducing the burden of malaria, among other diseases. In 2002, the Global Fund has committed over USD13 billion to malaria programs, and this funding has been crucial in supporting malaria control efforts worldwide.

Another important government initiative is the Roll Back Malaria Partnership, which is a global initiative aimed at coordinating and strengthening efforts to reduce the burden of malaria. The partnership is led by the World Health Organization and includes a wide range of stakeholders, including governments, international organizations, and civil society. Through the Roll Back Malaria Partnership, governments have committed to providing universal access to malaria prevention and treatment by 2030.

In addition to these global initiatives, many governments have also launched national programs aimed at combating malaria. For example, the government of Nigeria launched the National Malaria Elimination Program in 2016, with the goal of reducing the burden of malaria by 2020. The program includes a wide range of activities, such as the distribution of insecticide-treated bed nets, the provision of malaria diagnosis and treatment services, and the promotion of community-based interventions.

Governments have also implemented policies aimed at promoting the development and distribution of malaria therapeutics. For example, many countries have implemented policies aimed at reducing the cost of malaria medications. In some cases, governments have even provided free or subsidized medications to patients. In addition, many governments have implemented regulatory frameworks aimed at ensuring the quality and safety of malaria therapeutics.

Hence, the support of government initiatives has been crucial in driving the development and distribution of malaria therapeutics. These initiatives have provided funding and support for research and development activities, as well as for programs aimed at improving access to malaria prevention and treatment services. While there is still much work to be done in the fight against malaria, these government initiatives provide hope for a future where malaria is no longer a major public health concern. Hence creating lucrative opportunities for the growth of global malaria therapeutics market in the forecast period.

Recent Developments

Approval of tafenoquine: In 2018, the U.S. Food and Drug Administration (FDA) approved tafenoquine, a new drug for the prevention of relapse of Plasmodium vivax malaria. Tafenoquine is the first new drug to be approved for the prevention of relapse in over 60 years.

New antimalarial drug combinations: In 2019, a new antimalarial drug combination of lumefantrine and ferroquine was found to be effective against drug-resistant strains of malaria. Another combination, dihydroartemisinin-piperaquine and pyronaridine-artesunate, has also shown promise in clinical trials.

Development of long-acting therapies: Several long-acting therapies for the treatment of malaria have been developed in the last three years, including a new injectable formulation of artesunate that can provide protection for up to six months.

Advances in genetic testing: Advances in genetic testing have improved our understanding of the genetics of the malaria parasite, which could lead to the development of more targeted and effective therapies.

Increased use of natural products: There has been growing interest in the use of natural products for the treatment of malaria, including artemisinin and other plant-based compounds.

Use of digital technologies: Digital technologies, including mobile health platforms, have been used to improve the delivery of malaria treatments and to track the spread of the disease.

New vaccine candidates: Several new malaria vaccine candidates have entered clinical trials in the last three years, including a vaccine based on the circumsporozoite protein (CSP) that has shown promising results in early-stage trials.

Download Free Sample Report

Market Segmentation

Global Malaria Therapeutics market is segmented based on drug type, drug formulation, distribution channel, and region. Based on drug type, global malaria therapeutics market is segmented into artemisinin-based combination therapy (ACT), quinine, chloroquine, and others. Based on drug formulation, the global malaria therapeutics market is fragmented into tablets, capsules, injectables, and Others. Based on distribution channel, the global malaria therapeutics market is segmented into retail pharmacies, hospitals, online pharmacies. Based on region, global malaria therapeutics market is divided into North America, Europe, Asia Pacific, South America, Middle East & Africa.

Company Profiles

Novartis AG, Sanofi S.A, Pfizer Inc, GlaxoSmithKline Plc, Merck & Co Inc, F. Hoffmann-La Roche AG, Medicines for Malaria Venture, 60° Pharmaceuticals, Inc, Cipla Limited, Ajanta Pharma Limited are some of the key players of global malaria therapeutics market.

Report Scope:

In this report, global Malaria Therapeutics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

• Malaria Therapeutics Market, By Drug Type:
• Artemisinin-based combination therapy (ACT)
• Quinine
• Chloroquine
• Others
• Malaria Therapeutics Market, By Drug Formulatuion:
• Tablets
• Capsules
• Injectables
• Others
• Malaria Therapeutics Market, By Distribution Channel:
• Retail pharmacies
• Hospitals
• Online pharmacies
• Malaria Therapeutics Market, By Region:
• North America
• United States
• Mexico
• Canada
• Europe
• France
• Germany
• United Kingdom
• Spain
• Italy
• Asia-Pacific
• India
• South Korea
• Japan
• Australia
• Vietnam
• Indonesia
• Myanmar
• South America
• Brazil
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Egypt
• Turkey
• Nigeria

Competitive landscape

Company Profiles: Detailed analysis of the major companies present in the global Malaria Therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).